Resapp Health Stock

Resapp Health EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Resapp Health (RAP.AX) as of Jun 23, 2026 is -4.68.In the previous year, EV/EBIT (Enterprise Value to EBIT) was -4.8 — a change of -2.46% (higher).

EV/EBIT

-4.68

YoY

-2.46%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Resapp Health is 2026 -4.68 . EV/EBIT (Enterprise Value to EBIT) of Resapp Health was 2025 -4.8 . It decreases by -2.46% higher compared to the previous year.

The Resapp Health EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2004
0 base
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
0 base
Jan 1, 2010
0 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
YEARPRICE-TO-EBIT
2025 est -
2024 est -
2023 est -
2022 -9,16
2021 -20,98
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
2004 -
Access this data via the Eulerpool API
Get Free API Key

Resapp Health Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Resapp Health's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Resapp Health's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Resapp Health's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Resapp Health grows earnings faster than its peers.

Resapp Health Stock analysis

What does Resapp Health do? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resapp Health stock

EV/EBIT (Enterprise Value to EBIT) of Resapp Health amounted to -4.8 -4.68

Access this data via the Eulerpool API
Get Free API Key

Valuation — Resapp Health

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Resapp Health